Status:
WITHDRAWN
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema
Lead Sponsor:
Galderma R&D
Conditions:
Erythema
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare the efficacy and assess the safety of CD07805/47 gel 0.5% applied topically once daily for 29 days versus vehicle control, in subjects with moderate to severe c...
Eligibility Criteria
Inclusion
- Male or female, who is at least 18 years of age or older at screening visit.
- Presence of chronic persistent vascular facial erythema for ≥ 3 months by history.
- A Clinician's Erythema Assessment (CEA) score of ≥3 at Screening and at Pre-dose (T0) on Baseline/Day 1.
- A Patient Self Assessment (PSA) score of ≥3 at Screening and at Pre-dose (T0) on Baseline/Day 1.
Exclusion
- More than 2 facial inflammatory lesions (papules, pustules, and nodules).
- Presence of areas of significant scaling or crusting on the face.
- Presence of psoriatic lesions on the face.
- Presence of any other dermatological condition of the face that, in the opinion of the Investigator, may significantly interfere with the interpretation of the clinical trial results.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01882712
Last Update
November 6 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.